Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,384
Closed -$901K – 523
2026
Q2
$901K Sell
13,384
-34
-0.3% -$2.26K 0.09% 358
2026
Q1
$843K Buy
+13,418
New +$934K 0.08% 355
2025
Q4
– Sell
-11,645
Closed -$784K – 538
2025
Q3
$784K Buy
+11,645
New +$922K 0.12% 314
2025
Q1
– Sell
-6,223
Closed -$484K – 462
2024
Q4
$484K Sell
6,223
-34,301
-85% -$2.54M 0.14% 253
2024
Q3
$2.72M Buy
+40,524
New +$3.33M 0.88% 4
2023
Q2
– Sell
-3,322
Closed -$386K – 409
2023
Q1
$386K Buy
+3,322
New +$372K 0.23% 205

Other funds holding DXCM

Oak Thistle's DXCM Position: Q3 2026 in Review

Oak Thistle sold out of DexCom (DXCM) in Q3 2026, closing a stake of 13,384 shares — an estimated $901K sold.

Oak Thistle first reported a position in DXCM in Q1 2023 and held it in 6 quarters. The position peaked at $2.72M in Q3 2024. 863 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Oak Thistle reported no remaining DexCom position as of Q3 2026 after selling out during the quarter.
  • Oak Thistle sold 13,384 DexCom shares in Q3 2026, an estimated $901K.
  • Oak Thistle first reported a position in DexCom in Q1 2023 and held it in 6 quarters.
  • Oak Thistle's DexCom position peaked at $2.72M in Q3 2024.
  • 863 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Oak Thistle's 13F filing for Q3 2026, filed 21 Oct 2026.